Lumigan®
Bimatoprost 0.01% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in open angle glaucoma or ocular hypertension
One drop in the affected eye(s) once daily in the evening
IOP lowering stays within 0.9 mmHg of bimatoprost 0.03% with a third the worsening hyperemia.
OFF-LABELNot in the FDA label for this product
Chronic primary angle closure glaucoma
One drop once daily; the trial used bimatoprost 0.03%, not the 0.01% strength of this label
Randomized crossover · n=60
Observer-masked randomized crossover trial, 60 patients with chronic primary angle closure glaucoma and 54 completers (80 eyes), 6 weeks per arm. Bimatoprost 0.03% lowered IOP by 8.9 mmHg and latanoprost 0.005% by 8.4 mmHg from a baseline of 25.2 mmHg, a difference that was not statistically significant (P=0.23); adverse events, mostly mild ocular irritation, were reported by 81% on bimatoprost vs 40% on latanoprost (P<0.01).
Contraindications
Hypersensitivity to bimatoprost or any component
0.01% (0.1 mg/mL) solution, 2.5 mL, 5 mL, 7.5 mL
Prostaglandin analog that selectively mimics the effects of naturally occurring prostamides. It is believed to lower IOP by increasing aqueous humor outflow through both the trabecular meshwork and the uveoscleral routes.
Warnings & Precautions
- Iris pigmentation: Typically, the brown pigmentation around the pupil spreads concentrically toward the periphery. It is likely to be permanent after discontinuation, its long term effects are not known, and it may not be noticeable for several months to years. It reflects more melanin in melanocytes, not more melanocytes. Inform patients of the possibility of increased pigmentation. Treatment can be continued in patients who develop noticeably increased iris pigmentation, but examine them regularly.
- Periorbital and lash pigmentation: Increased pigmentation of the periorbital tissue (eyelid) and eyelashes has been reported, and pigmentation is expected to increase as long as dosing continues; reported reversible in some patients after discontinuation.
- Eyelash changes: LUMIGAN 0.01% may gradually change eyelashes and vellus hair in the treated eye, including increased length, thickness, and number of lashes; these changes are usually reversible upon discontinuation. They may result in a disparity between eyes in length, thickness, pigmentation, number, or direction of lash growth.
- Intraocular inflammation: Prostaglandin analogs including bimatoprost have been reported to cause intraocular inflammation; caution with active inflammation such as uveitis, which may be exacerbated.
- Macular edema: Macular edema, including cystoid macular edema, has been reported; caution in aphakia, pseudophakia with a torn posterior lens capsule, or other known risk factors for macular edema.
- Bacterial keratitis: Reported with contaminated multiple-dose ophthalmic containers, in most cases in patients with concurrent corneal disease or a disrupted ocular epithelial surface.
- Contact lens use: Benzalkonium chloride may be absorbed by and discolor soft contact lenses; remove lenses before instillation, and they may be reinserted 15 minutes after.
Common Side Effects
- Ocular, most common: Conjunctival hyperemia 31% in a 12-month study, with approximately 1.6% discontinuing because of it.
- Ocular, 1% to 4%: Conjunctival edema, conjunctival hemorrhage, eye irritation, eye pain, eye pruritus, punctate keratitis, instillation site irritation, blurred vision, reduced visual acuity.
- Periocular, 1% to 4%: Eyelid erythema, eyelid pruritus, growth of eyelashes, hypertrichosis, skin hyperpigmentation.
- Pigmentation: Iris hyperpigmentation and blepharal pigmentation.
- Periorbital fat atrophy: Skin tightness with deepening of the eyelid sulcus, eyelid ptosis, enophthalmos, and eyelid retraction; postmarketing.
- Other ocular, postmarketing: Dry eye, foreign body sensation, eye discharge, eye edema, increased lacrimation, photophobia, eye allergy and allergic dermatitis.
- Systemic, postmarketing: Headache, dizziness, hypertension, asthma-like symptoms, dyspnea.
Pregnancy: No adequate and well-controlled studies in pregnant women; postmarketing experience shows no increase in major birth defects or miscarriage. Oral dosing during organogenesis caused abortion and early delivery in mice and rats at oral doses at least 33 times (mice) and 94 times (rats) the human exposure to bimatoprost 0.03% dosed bilaterally once daily by AUC, and these effects were not seen at 2.6 times (mice) or 47 times (rats). Oral dosing of pregnant rats from organogenesis to the end of lactation reduced gestation length and fetal body weight and increased fetal and pup mortality at oral doses at least 41 times the human systemic exposure. Use only if the potential benefit justifies the potential risk to the fetus.
Lactation: Unknown whether topical ocular use yields detectable quantities in human milk; present in rat milk at an IV dose 970 times the recommended human ophthalmic dose on a mg/m2 basis; however, no animal data is available at clinically relevant doses.
Not recommended below 16 years because of potential safety concerns related to increased pigmentation with long-term chronic use.